RT Journal Article
SR Electronic
T1 Treatment of Severe COVID-19 with Convalescent Plasma in the Bronx, NYC
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.02.20242909
DO 10.1101/2020.12.02.20242909
A1 Yoon, Hyun ah
A1 Bartash, Rachel
A1 Gendlina, Inessa
A1 Rivera, Johanna
A1 Nakouzi, Antonio
A1 Bortz, Robert H.
A1 Wirchnianski, Ariel S.
A1 Paroder, Monika
A1 Fehn, Karen
A1 Serrano-Rahman, Leana
A1 Babb, Rachelle
A1 Sarwar, Uzma N.
A1 Haslwanter, Denise
A1 Laudermilch, Ethan
A1 Florez, Catalina
A1 Dieterle, M. Eugenia
A1 Jangra, Rohit K.
A1 Fels, J. Maximilian
A1 Tong, Karen
A1 Mariano, Margarette C.
A1 Vergnolle, Olivia
A1 Georgiev, George I.
A1 Herrera, Natalia G.
A1 Malonis, Ryan J.
A1 Quiroz, Jose A.
A1 Morano, Nicholas C.
A1 Krause, Gregory J.
A1 Sweeney, Joseph M.
A1 Cowman, Kelsie
A1 Allen, Stephanie
A1 Annam, Jayabhargav
A1 Applebaum, Ariella
A1 Barboto, Daniel
A1 Khokhar, Ahmed
A1 Lally, Brianna J.
A1 Lee, Audrey
A1 Lee, Max
A1 Malaviya, Avinash
A1 Sample, Reise
A1 Yang, Xiuyi A.
A1 Li, Yang
A1 Ruiz, Rafael
A1 Thota, Raja
A1 Barnhill, Jason
A1 Goldstein, Doctor Y.
A1 Uehlinger, Joan
A1 Garforth, Scott J.
A1 Almo, Steven C.
A1 Lai, Jonathan R.
A1 Gil, Morayma Reyes
A1 Fox, Amy S.
A1 Chandran, Kartik
A1 Wang, Tao
A1 Daily, Johanna P.
A1 Pirofski, Liise-anne
YR 2020
UL http://medrxiv.org/content/early/2020/12/04/2020.12.02.20242909.abstract
AB Convalescent plasma with severe acute respiratory disease coronavirus 2 (SARS-CoV-2) antibodies (CCP) may hold promise as treatment for Coronavirus Disease 2019 (COVID-19). We compared the mortality and clinical outcome of patients with COVID-19 who received 200mL of CCP with a Spike protein IgG titer ≥1:2,430 (median 1:47,385) within 72 hours of admission to propensity score-matched controls cared for at a medical center in the Bronx, between April 13 to May 4, 2020. Matching criteria for controls were age, sex, body mass index, race, ethnicity, comorbidities, week of admission, oxygen requirement, D-dimer, lymphocyte counts, corticosteroids, and anticoagulation use. There was no difference in mortality or oxygenation between CCP recipients and controls at day 28. When stratified by age, compared to matched controls, CCP recipients <65 years had 4-fold lower mortality and 4-fold lower deterioration in oxygenation or mortality at day 28. For CCP recipients, pre-transfusion Spike protein IgG, IgM and IgA titers were associated with mortality at day 28 in univariate analyses. No adverse effects of CCP were observed. Our results suggest CCP may be beneficial for hospitalized patients <65 years, but data from controlled trials is needed to validate this finding and establish the effect of ageing on CCP efficacy.Competing Interest StatementKC is a member of the Scientific Advisory Board of Integrum Scientific, LLC. In addition, KC has a SARS-CoV-2 spike neutralization assay patent pending, and a SARS-CoV-2 spike antibody assay patent pending. JL reports grants from Adimab LLC, grants from Integrated BioTherapeutics, grants from Mapp Biopharmaceutical, personal fees from Johnson & Johnson, personal fees from Celdara Medical. In addition, JL has a COVID-19 antibody diagnostic patent pending. Other authors have declared that no conflict of interest exists.Funding StatementHY was supported by NIH/National Center for Advancing Translational Service (NCATS) Einstein-Montefiore CTSA Grant Number UL1TR001073. LP was supported in part by NIH grants AI 123664, AI 143453, NCATS 3UL1TR002556-04S1 and a grant from the Mathers Foundation. KC was supported in part by NIH grants U19AI142777 and R01AI32633 and a COVID-19 Pilot Award from Albert Einstein College of Medicine. JRL was supported by the NIH (R01-AI125462) and a COVID-19 Pilot Award from Albert Einstein College of Medicine. SCA was supported by R01AI145024, the Wollowick Family Foundation Chair in Multiple Sclerosis and Immunology, and Janet & Martin Spatz and the Helen & Irving Spatz Foundation. Additional support provided by the Albert Einstein Macromolecular Therapeutics Development Facility, the Einstein-Rockefeller-CUNY Center for AIDS Research (P30AI124414), and the Albert Einstein Cancer Center (P30CA013330). JPD was supported by NIAID R21AI141367. MCM and GIG were supported by an NIH Training Program in Cellular and Molecular Biology and Genetics (T32-GM007491). KT, JAQ, RJM, RHBIII and GK were supported by an NIH Medical Scientist Training Program (T32 GM007288) at Albert Einstein College of Medicine. This study was supported in part by a US Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA) grant contract 75A50120C00096, National Center for Advancing Translational Sciences (NCATS) grant UL1TR002377, Schwab Charitable Fund (Eric E Schmidt, Wendy Schmidt donors), United Health Group, National Basketball Association (NBA), Millennium Pharmaceuticals, Octopharma USA, Inc, and the Mayo Clinic.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The retrospective cohort study, the donor plasma procurement protocol and the use of the expanded access protocol was approved by the Albert Einstein College of Medicine Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.